A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.
Researchers say breast cancer-related deaths have dropped by 44% since 1989, due to advancements in treatment and early ...
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali ... demonstrated statistically significant overall ...
Under this two-hit model, Brugge says, one normal copy of BRCA1 ought to be able to carry out DNA repair even when the other ...
Researchers also are trying to understand the racial disparities in breast cancer diagnosis and mortality. Black women have a lower survival rate for breast cancer than white women, no matter the ...
especially rising obesity rates, are likely driving the rise in cancer. Breast cancer is the second most common cancer in women, following skin cancer. This year, ACS estimates there will be ...
TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on ARVN stock, giving a Buy rating on October 22. Tyler Van Buren’s ...
According to a report that came out just earlier this month from the American Cancer Society, the rate ... breast cancer," Dr. Brown said. "We know that it leads to better outcomes in terms of ...
Health experts say mammograms are critical to helping detect breast cancer early. American Cancer Society research shows that despite significant drops in the mortality rate, breast cancer ...
“Recent trends in breast cancer show that while overall incidence rates have stabilized ... are game changers in terms of survival. Chen cites Ribociclib, a drug used for many years for those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback